This Is MS Multiple Sclerosis Community: Knowledge & Support

Looks decidedly injectable

_________________
John
I am what I am

I was beyond confused at the title of your post, and then I remembered Borat...

I did a quick look for more information on this therapy, and came up empty, at least in English-language. We'll keep an eye out for it.

_________________
Disclaimer: Any information you find on this site should not be considered medical advice. All decisions should be made with the consent of your doctor, otherwise you are at your own risk.

I found this from the pharmaceutical company's site.
http://www.farmacija.co.ba/ridfar.htm

Are Enkorten and FAR404 the same thing?

NHE

NHE, I think so. I got to the same place in a similar post in the pipeline section.

I took a very quick look at the information available in Bosnian language-- didn't find too much solid stuff out there-- it looks like Phase II was completed in December. The drug is an immunomodulatory agent of some sort (sorry, don't speak either English or any other language well enough to understand dr-speak). It is administered sub-Q; was tested on 60 RR (I think) patients, half of whom were controls. Again, all I was able to find are references to "many" of them experiencing improvement in MRI and EDSS, as well as in bladder, bowel control, eye function, coordination etc. Looks like it's proceeding to Phase III; some of the testing centers either were or will be (I couldn't understand that part) in Germany.

thanks Connie!

_________________
Disclaimer: Any information you find on this site should not be considered medical advice. All decisions should be made with the consent of your doctor, otherwise you are at your own risk.

The Farmacija site lists Zahida Ademović as the R&D manager. A search on PubMed yields several papers with Z. Ademović listed as an author. A few of these abstracts discuss cell adhesion via beta-integrins, e.g.,

The recognition of adsorbed and denatured proteins of different topographies by beta2 integrins and effects on leukocyte adhesion and activation. Biomaterials. 2005 Jun;26(16):3039-53.

It may be the case that the drug in trials by Farmacija affect cell adhesion.

NHE

hello and sorry for my bad english,i`m from greece but i know to speak bosnian.
They say that in phase2 trial (30 patients on active drug with average edss 3.5 and 30 patients on placebo with average edss 2.5) the drug compared to placebo reduce the relapses by 60%,edss score reduced by 26% .The drug in bosnia is approved and covered by insurance companys,also they say that foreign patients can buy the drug.

Hi Crue,

Your English is good. Thank you for the translation. Did you find a reference to the phase II study?

ThinkingOutLoud

Crue
Thank you for taking the time to translate. Same to you connib
NN